Drugs / M6495
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03583346 | Aug 2018 → Jul 2019 | osteoarthritis, knee | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT03224702 | Sep 2017 → Aug 2018 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M6495 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03583346 ↗ |
| Modality | Protein / enzyme biologic | “M6495 (Anti-ADAMTS-5 Nanobody)” NCT03583346 ↗ |
| Route | Subcutaneous | “Subcutaneous Injections” NCT03583346 ↗ |
| Target | ADAMTS5 | “Anti-ADAMTS-5 Nanobody” NCT03583346 ↗ |